Director of Investments, Roche Venture Fund
Formerly the General Partner Emeritus at CMEA Capital, Karl has a great passion for science and innovation and has been privileged to work alongside many talented entrepreneurs. The management teams at Ambrx, Ensemble Discovery, Ilypsa, Intellikine, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, Tetraphase, and Xenoport – all have contributed to Karl’s wealth of experience executing visionary plans. Prior to joining CMEA, Karl worked in biotech business development at Millennium. He was one of the first employees of Tularik, and the Whitehead Institute.